Rating: Cautiously Bullish | Target Price Range: HK$11.4–13.5 | Current Price: HK$6.99 (close on 2026-10-09) | Margin of Safety: ~63% (= (base-case fair value floor 11.4 − current price)/current price) | Time Horizon: 12–18 months | Probability-weighted expected value ~HK$12.1 (~+74% vs. current price)
MedTech MicroTech Medical (微泰医疗) is a first-tier Chinese diabetes management device player with a combined "CGM + patch insulin pump" portfolio: FY2025 revenue of RMB 661 million (+91.2%) with its first annual profit since listing; 2026H1 revenue of RMB 414 million (+68.4%), net profit attributable to shareholders of RMB 40.27 million, gross margin rising to 57.7%, and positive operating cash flow. The direction of the profitability inflection is established, but earnings quality remains distorted by interest income/subsidies/FX effects. The current price of HK$6.99 implies a market cap of HK$2.90 billion, of which net cash is ~HK$1.98 billion (HK$4.77 per share, 68% of market cap); EV is only ~HK$920 million with EV/S(TTM) ≈ 0.97x — the market is effectively pricing "perpetual zero growth in core earnings + cash at face value," close to treating the European patent injunction and VBP fears as the base case. This report judges the discount to be significantly excessive (base-case fair value HK$11.4–13.5), but there is no endogenous mechanism for convergence: extremely low liquidity (average daily turnover ~HK$430K–2.58M), no dividend policy, and removal of the "-B" flag is predicated on reaching a HK$4.0 billion market cap; re-rating must be validated step-by-step via events such as the UPC patent litigation ruling, the FY2026 annual report (March 2027), and G9 volume ramp. Cautiously bullish; the core constraints are time cost and the asymmetric tail risk of the European injunction.
FY2025 net profit attributable of RMB 40.15 million marked the first annual profit since listing; 2026H1 net profit attributable was RMB 40.27 million, exceeding the RMB 36 million floor of the positive profit alert issued in late July; gross margin 57.7% (+6.0pp YoY), selling expense ratio 28.5% (−9.2pp), operating cash flow RMB 57.41 million — the statement-level evidence of operating leverage is complete. However, three flaws must be presented honestly: first, 2026H1 interest income (RMB 21.92 million) + other income (RMB 11.85 million) + investment income (RMB 3.95 million) totaled RMB 37.72 million, covering ~94% of net profit — book earnings remain highly dependent on returns from idle funds; second, core pre-tax operating profit after excluding interest/FX/subsidies is ~RMB 35–45 million (our estimate, sensitive to methodology), having turned positive from ~−RMB 13 million in 2025, but the magnitude should be understood as a range; third, 2026H1 net profit declined 5.1% sequentially versus 2025H2 (RMB 42.44 million), and FX losses have been negative for three consecutive reporting periods (the company explicitly has no FX hedging policy) — the ultimate basis for "inflection confirmed" should be the FY2026 annual report — H2 will be the first full half-year after the injunction took effect, with a high base.
Of the HK$2.90 billion market cap (2026-10-09 close of HK$6.99 × 414.9 million shares), net cash is ~HK$1.98 billion — as of 2026-06-30: cash and cash equivalents RMB 1.537 billion + large-denomination certificates of deposit RMB 254 million + trading financial assets, less short-term borrowings of RMB 74 million, equivalent to HK$1.978 billion, or HK$4.77 per share, 68% of market cap. EV is thus only ~HK$920 million (~RMB 800 million), implying EV/S(TTM) ≈ 0.97x (TTM revenue RMB 829 million) and an ex-cash 2027E P/E of ~4.9x (base-case net profit RMB 165 million); versus Dexcom's P/S of ~6.9x, the price paid for growth under an EPV framework is only ~7%. The market has its logic for this pricing: ~29% of net cash is IPO proceeds with committed uses (to be deployed by end-2027), the company has no dividend policy, buybacks are small, and the cash discount on an 18A small cap can persist for a long time — the "mismatch" is real, but convergence depends on external events rather than happening automatically; that is why this thesis carries a confidence of only 0.60.
Domestic revenue in 2026H1 grew +109.4% YoY (RMB 256 million); CGM revenue (global basis) was RMB 313 million, +118.7% YoY. On the industry side, China's CGM penetration is still early-stage (~6.9% for Type 1, ~1.1% for Type 2, per CIC's 2020 figures; versus 25.8% Type 1 in the US and 18.2% in Europe). The continuation of national subsidies in 2026 (CGM subsidies of up to 30%), combined with e-commerce channels, is currently the strongest payment-side catalyst. Product succession is clear: the new split-type AiDEX G9 (15-day single wear, reusable transmitter, MARD 8.66%) was approved by the NMPA on 2026-09-07 and went on sale in October via JD.com and other channels. Important caveat: the claim at the Digital Trade Expo that "over 10,000 units sold within 2 hours of launch" is media-reported launch-event data; at an industry unit price of RMB 96–123 per unit, it translates to only ~RMB 1 million level — immaterial to annual revenue and not a basis for judging volume ramp. The truly falsifiable checkpoints are 2026 Double 11 shipments and the FY2026 annual report's CGM segment growth rate (a drop below 50% would be a warning).
On 2026-02-06, the Hague Local Division of the Unified Patent Court granted Abbott's interim measures application on patent EP3960072, banning sales of MedTech's Vista System and DiaExpert System CGMs, covering UPC member states plus Spain; Abbott has filed main proceedings, the company has submitted defense and counterclaim materials, and hearings have not yet begun. Quantified exposure: the company does not disclose the European revenue split; assuming Europe accounts for 35%–55% of overseas revenue, annual revenue exposure is ~RMB 120–190 million (13%–20% of total revenue). Erosion is already visible in the financials: overseas revenue growth dropped abruptly from +227.2% in FY2025 to +27.5% in 2026H1, timing consistent with the injunction, with no separate company explanation. The risk asymmetry lies in: within 18 months, Abbott won three consecutive interim injunction applications — against Sinocare (The Hague, 2025-10; upheld on appeal 2026-04), MedTech (2026-02), and SiBionics (Milan, 2026-09, same EP3960072) — and the Hague ruling already rejected the defendants' patent-invalidity defense — the probability of losing the main proceedings or a further injunction against LinX S1/G9 in separate cases is not low (estimated at ~55%–70% in this report). The current injunction does not yet cover LinX S1 (CE-marked 2026-04) or G9, which is the company's product-switching hedge, but there is no court-level non-infringement confirmation. Separately, an arbitration over an overseas distribution agreement has been constituted but remains pending.
Liquidity: average daily turnover over the past 30 trading days was ~HK$430K (an alternative 3-month measure ~HK$2.58M), both below the 0.1%-of-market-cap threshold (~HK$2.9 million/day); many trading days since October have seen near-zero turnover; southbound eligibility is independently unverified, institutions are in practice unable to build positions, and any downside on negative news will be amplified by thin liquidity. Removal of the "-B" flag requires a market cap of HK$4.0 billion (~HK$9.6/share) or satisfaction of profit/cash-flow tests — it is the result, not the cause, of a re-rating, and cannot be treated as an exogenous catalyst. VBP: as of October 2026, CGM has not been included in any national or inter-provincial alliance volume-based procurement, but blood-glucose test strip VBP and the 2021 insulin special VBP (average price cut of 48%) set preced; if it lands within 12–18 months (probability ~25%), a scenario of 30%–50% in-hospital ASP cuts would significantly compress net margin — since the company's domestic revenue is mainly e-commerce retail, the pass-through of price cuts to the retail channel is uncertain and should be treated as a range rather than a point estimate. Together, these dictate that the value realization of this undervalued trade is "event-driven, step-by-step verified," and the time cost may be high.
| Metric (RMB) | FY2023 | FY2024 | FY2025 | 2026H1 (latest period) |
|---|---|---|---|---|
| Operating revenue (RMB 100M) | 2.53 | 3.46 | 6.61 | 4.14 (+68.4% YoY) |
| Net profit attributable (RMB 100M) | −1.25 | −0.63 | 0.40 | 0.40 (prior-year period −0.02) |
| Recurring net profit (ex-non-recurring) (RMB 100M) | — | — | 0.28 (company-disclosed ex-non-recurring) | ~0.32 (our estimate) |
| Gross margin | 47.7% | 52.9% | 54.1% | 57.7% (+6.0pp) |
| Net margin | −49.4% | −18.3% | 6.1% | 9.7% |
| Selling expense ratio | — | 59.9% | 33.8% | 28.5% |
| R&D expense (RMB 100M) | — | 0.77 | 0.76 | 0.42 (+28.9%) |
| Operating cash flow (RMB 100M) | −1.53 | −1.21 | 0.33 | 0.57 |
| Free cash flow (RMB 100M, OCF−CapEx) | −1.82 | −2.04 | −0.06 | +0.08 |
| Cash + cash-like (RMB 100M, period-end) | — | — | 15.07 (cash and cash equivalents basis) | 17.92 (incl. CDs of 2.54) |
| Interest-bearing debt (RMB 100M) | — | — | — | 0.74 (all pledged borrowings within 1 year) |
| Net cash (RMB 100M) | — | — | — | 17.18 (2026-06-30) |
| Gearing ratio | — | — | — | 12.9% |
Note: The company reports under Chinese Enterprise Accounting Standards and does not disclose a Non-IFRS adjusted basis; "recurring net profit" for 2025 is the company's annual-report ex-non-recurring figure, while 2026H1 is this report's estimate (net profit attributable excluding other income and non-operating items). Balance-sheet stock items are all from the latest period (2026-06-30). The company is in a net cash position, so net debt/EBITDA is not applicable.
Drivers of metric changes (YoY ≥ ±20% summary, with management explanations): ① Revenue +91.2%/+68.4% — "rapid growth in domestic and international sales of continuous glucose monitoring systems"; ② Overseas revenue FY2025 +227.2% — "LinX successfully included in national reimbursement systems across multiple countries… newly obtained regulatory registrations in over 20 countries"; ③ Gross margin +6.0pp — "significantly higher share of CGM sales, plus release of production scale efficiencies, higher production automation, and various cost-reduction measures"; ④ Selling expense ratio 59.9%→28.5% — "strong market acceptance of AiDEX X making commercialization more efficient; implementation of comprehensive budgeting and cost reduction"; ⑤ Administrative expenses +68.1% — "increase in professional fees"; ⑥ Finance costs swinging from net income to net expense — "depreciation of the USD and HKD against the RMB during the period" (FX losses of RMB 32.83 million vs. RMB 5.33 million in the prior-year period); ⑦ Inventory write-down losses +142% — unexplained by the company (see Section VIII red flags); ⑧ Construction in progress RMB 0.01→1.84 (100M) — a new round of investment following completion and capitalization of the 44,000 sqm new facility in 2025.
Revenue RMB 414 million (+68.4%), CGM revenue RMB 313 million (+118.7%), gross margin 57.7% (+6.0pp), net profit attributable RMB 40.27 million (prior-year period: loss of RMB 2.29 million), operating cash flow RMB 57.41 million (prior-year period RMB 4.43 million), cash received from sales of RMB 449 million exceeding revenue for the period. Two structural points stand out: first, the growth engine has switched — domestic +109.4% is now the main driver, while overseas slowed markedly to +27.5%; second, profit is not linear sequentially — 2026H1 net profit (RMB 40.27 million) was −5.1% versus 2025H2 (RMB 42.44 million), with FX losses of RMB 32.83 million (~81% of pre-tax profit) as the main drag. Versus expectations: the company's late-July positive profit alert set floors of RMB 400 million revenue/RMB 36 million net profit; actuals beat by 3.5% and 11.9% respectively. On results day (2026-08-21) the stock closed flat at HK$7.15 on light volume; after the interim report, CICC/China Construction Securities (中信建投) maintained Buy (2026–28E net profit RMB 0.87/1.79/2.42 (100M)) and Huachuang maintained Strong Buy (target price HK$12) — coverage is only 2–3 brokers with no reliable consensus database, so this report does not conclude on behalf of the market that "the beat is priced in," but only confirms that the profit-alert guidance was delivered and that sell-side commentary is positive.
Model in brief: A consumable-repurchase medical device business — CGM sensors contribute 75.6% of revenue as a high-frequency 14–15 day repurchase product; the insulin pump is "device + consumable"; BGM test strips are a traditional traffic driver. Full-stack in-house R&D and manufacturing (core sensor enzyme-membrane/probe processes made in-house; 44,000 sqm new Hangzhou facility completed 2025); channels are domestic in-hospital (3,600+ hospitals) + out-of-hospital e-commerce + overseas distribution (120+ countries, 101 overseas registrations). Revenue is strongly recurring, but pricing power is limited (domestic unit price fell from RMB 400–600/unit in 2021 to RMB 96–123); profitability improvement comes from product mix upgrading and scale effects rather than price increases.
Cash content of earnings: OCF/net profit — during the loss-making 2023/2024, the cash flow gap was smaller than book losses; 0.81 in 2025 and 1.43 in 2026H1 (cash received from sales of RMB 449 million ＞ revenue of RMB 414 million), indicating good collection quality. FCF/net profit: −0.16 in 2025 (new-facility CapEx drag), turning positive to +0.2 in 2026H1 — the expansion peak has passed (2024 CapEx RMB 83 million, CapEx/depreciation 8.0x), falling back to RMB 39 million (2.8x) in 2025. Recurring earnings check: FY2025 ex-non-recurring net profit RMB 28 million vs. net profit attributable of RMB 40.15 million (recurring ratio 70%), with non-recurring items mainly government subsidies (subsidies recognized in P&L of RMB 14.47 million, 36% of net profit attributable) and disposal gains on financial assets; more critically, interest income of RMB 47.78 million ＞ net profit attributable — after excluding returns on idle funds, 2025 core operating profit was still negative (~−RMB 13 million), turning positive to ~RMB 35–45 million in 2026H1 (estimated, methodology-sensitive). Return on capital: ROIC ~1.6% (diluted by RMB 1.5 billion-level IPO cash sitting on the balance sheet); excluding net cash, returns on operating assets are significantly higher; versus an equity cost of ~12%, the overall return has not yet crossed the threshold, but the slope is upward — mainly because cash has not yet been deployed rather than poor asset profitability. CapEx quality: the company does not disclose a maintenance/growth split; by capacity measures, 2024–2025 was the expansion peak (pump 30,000 units + consumables 3.6 million units project, budget RMB 244 million); of 2026H1 cash CapEx of RMB 49.47 million, items include line upgrades and new-facility phase two; on a zero-growth basis, maintenance spend roughly offsets depreciation and amortization (~RMB 28 million annualized). Red flags: customer concentration (top five customers 33.8%; top five receivables share 53.99%→60.19%); profit dependence on interest and subsidies; the domestic e-commerce subsidiary has negative net assets, with the parent-company statements having fully provisioned RMB 261 million of receivables due from it (eliminated on consolidation).
Consistency between words and deeds: relatively consistent (pragmatic, slightly conservative). ① The 2026-07-30 profit warning committed to "revenue of no less than RMB 400 million and net profit of no less than RMB 36 million" → actual results of RMB 414 million / RMB 40.27 million, both delivered and above the lower bounds; ② At 2025 interim results, the company described itself as "slightly loss-making" → turned profitable in FY2025 (RMB 40.15 million); ③ The FY2025 annual report committed to advancing CGM new products / second-generation pump / artificial pancreas registrations →密集 delivered: LinX S1 obtained CE (2026-04), the second-generation pump obtained NMPA adult approval (2026-07), and G9 obtained NMPA approval (2026-09); however, the PanCares artificial pancreas has slipped beyond the company's stated "expected launch next year," qualifying as partial delivery. Shareholder friendliness: neutral. No dividends ever paid since listing; ongoing buybacks (cumulative repurchase of 8.2535 million H shares since 2023-11, representing 4.88% of H shares; as of 2026-09-30, treasury shares of 6.1689 million shares, representing 1.46% of total share capital), but the amounts are small; no dilutive actions such as rights issues or convertible bonds since listing — neither generous nor predatory. Risk signals: Chairman Zheng Pan concurrently serves as both Chairman and CEO (a multi-year deviation from the Corporate Governance Code provision C.2.1 with an explanatory exemption); in November 2025, the actual controller reduced holdings twice, totaling ~2.99 million shares / ~HK$19.86 million (at HK$6.04 / HK$6.90, close to the current price); in 2026-08, a new raw material procurement framework agreement was signed with Hangzhou Shukang, in which the actual controller holds a 95.65% stake (cap of RMB 7.5 million — a small amount, but pricing fairness requires ongoing monitoring).
| Segment | 2026H1 Revenue Share | Gross Margin (FY2025, estimated) | 2026H1 YoY | One-sentence business logic |
|---|---|---|---|---|
| CGM monitoring systems | 75.6% | 57.2% | +118.7% | High-frequency consumable repurchases + volume growth at home and abroad, the absolute growth engine |
| Insulin pump systems (Equil) | 9.7% | 68.0% | −3.2% | The only domestically approved patch pump; high margin but slow domestic ramp, reliant on international markets |
| BGM glucometers | 13.2% | 32.4% | −4.6% | Traditional red-ocean business; funnels hospital channel access for CGM/pumps |
Based on FY2025 revenue × gross margin, the gross profit structure is roughly: CGM ~72%, pumps ~17%, BGM ~10% — the profit driver is CGM, not the highest-margin pump. The gross margin gap spans 35.6 percentage points (pump 68% vs BGM 32.4%): the pump is a high-value therapeutic device with a favorable competitive landscape (80%+ of the domestic market held by imported brands), while BGM is a fully commoditized, saturated red ocean; CGM sits in the middle, with margins rising each period on scale effects. By region: in 2026H1, domestic accounted for 62.4% (+109.4%) vs overseas 37.6% (+27.5%), reversing the FY2025 pattern where overseas exceeded half — the growth engine has switched to domestic, while overseas is suppressed by the European ban.
Accounting red flags: ① Jump in inventory write-downs — RMB 9.12 million in 2025 (+142%), with 2026H1's RMB 4.98 million in just half a year already exceeding FY2024's full year; the company has not explained this, possibly reflecting phase-out of older models; ② Profit dependence on government grants and interest income (see Section V); ③ Rising receivables concentration (top five: 53.99% → 60.19%), with expanding exposure to large overseas distributors; ④ Newly established related-party supply arrangement (Shukang procurement; disclosed competitive bidding process); ⑤ Persistent losses at the domestic e-commerce subsidiary, fully provisioned by the parent — suggesting weak profitability of the domestic direct e-commerce operation. Cross-period consistency: ① Overseas revenue growth of +218% (2025H1) → +227.2% (FY2025) → +27.5% (2026H1), a drop of ~200 percentage points, yet the company still claims "rapid international sales growth" — inconsistent with note-level data; ② Net finance income of +RMB 71.56 million (2024) → +RMB 29.18 million (2025) → −RMB 12.75 million (2026H1), declining year by year, unexplained by the company; ③ Systematically rising intensity of inventory provisions, unexplained; ④ Four consecutive quarters of gross margin improvement (47.7% → 57.7%) alongside declining selling expense ratio (59.9% → 28.5%) — the explanation and data are consistent (mix upgrade + scale effects). Overall judgment: no signs of systematic financial engineering, but two transparency gaps — "the divergence between overseas high-growth rhetoric and regional data" and "unexplained inventory provisions" — warrant continued tracking.
Current market data and percentile (closing price HK$6.99, 2026-10-09): market cap HK$2.90 billion ≈ RMB 2.519 billion (FX rate 0.86855); net cash HK$1.978 billion; EV HK$922 million. PE(TTM) 30.5x, PE (2025 static) 65.2x — the company only turned profitable in 2025, and profits contain interest and FX noise, so the PE percentile is mechanically elevated, for reference only, not the headline metric; PB 1.24x (8th percentile over the past 1 year, ~50th percentile over the past 5 years; assets are mainly cash + capacity, zero goodwill, so PB is an appropriate metric); P/S(TTM) 3.04x, EV/S(TTM) 0.97x — the latter is the headline metric for this case; forward: 2026E PE ~25x (own-estimate net profit RMB 100 million), 2027E PE ~15x, ~4.9x 2027E PE excluding cash, PEG (2026–27E) ~0.23. Peer comparison:
| Company | P/E(TTM) | P/S(TTM) | Revenue growth | Notes |
|---|---|---|---|---|
| Medtrum Technologies-B | 30.5x | 3.04x | +68.4% (2026H1) | Net cash = 68% of market cap |
| Dexcom (US) | 33.0x | ~6.9x | +14–16% | Global CGM #2, MARD benchmark |
| Sinocare (A-share) | 69.7x | 1.88x | +12.1% (2026H1) | Profit thinned by CGM investment phase |
| Yuwell Medical (A-share) | 23.2x | 3.30x | −1.9% (2026H1 net profit −29.9%) | Platform medical device company, CGM second tier |
Market-implied expectations: EV of RMB 801 million ÷ 10.5% capitalization rate ≈ implied perpetual free cash flow of RMB 84 million/year — precisely the midpoint of the 2026H1 core earnings annualized range (RMB 76–89 million). In one sentence: the current price requires Medtrum to "perform exactly as it does today, and never grow again," whereas reality is an early-penetration company with revenue +68% and gross margins rising quarter by quarter; EV/S of 0.97x vs Dexcom's 6.9x means the market is simultaneously pricing both the European ban and centralized procurement at the most pessimistic branch. Reverse check: if the bear case holds (permanent European ban + 30% centralized-procurement price cut), 2027E net profit of ~RMB 35–50 million × 15x ≈ RMB 530–750 million ≈ current EV — i.e., the current EV exactly equals the bear-case business value, so the judgment that "the market is treating the bear case as the base case" holds in both directions.
Three-tier value (EPV): Asset value = net cash per share of HK$4.77 (floor reference; ~29% of it is committed-purpose IPO proceeds, counted at par in this snapshot); EPV (zero-growth operating value): annualizing 2026H1 core operating profit excluding interest/FX/grants (conservative ×2, below the actual 2025 H2/H1 ratio of 1.69x) ≈ RMB 76 million FCFF/year; discounting at 12% with a firm-level bridge (tax 15%, D&A ≈ maintenance CapEx, ΔWC ≈ 0) yields EPV of ~HK$6.53/share (range 6.2–7.4, sensitivity at discount rates of 10.5%–15%); the growth option residual, current price minus EPV, is ~7% — the market is paying less than ten cents on the dollar for all future growth. Note: for an 18A-B name with average daily turnover in the hundreds of thousands of HKD, a required market return above 12% is entirely reasonable; each 3-percentage-point rise in the discount rate lowers EPV by ~HK$0.35; hence "growth is nearly free" is a directional judgment, not a precise measurement.
Three scenarios and odds (anchoring discipline: base/bull exit PE anchored to Yuwell's 23.2x and Dexcom's forward 27–28x, with a small-cap liquidity discount applied to 16–19x / 24–26x, independent of the company's current multiple; the company's ~15x 2027E PE shown for comparison only):
| Scenario | Probability | Fair value range (HKD) | vs current price | Key assumptions |
|---|---|---|---|---|
| Bear | 30% | 5.0–6.5 | −28% ~ −7% | Main lawsuit lost or ban extended to S1/G9 + domestic ASP down 15–25%: 2027E net profit RMB 30–50 million × 13–16x + net cash RMB 1.65 billion; deep-bear sub-case (further ban + centralized procurement) 5.0–5.5, extreme tail near net cash of 4.4–4.8 per share |
| Base | 45% | 11.4–13.5 | +63% ~ +93% | Main lawsuit settled/limited in scope; Europe sustained by S1/G9 and non-EU markets; 2027E net profit RMB 150–165 million × 16–19x + net cash RMB 1.72 billion |
| Bull | 25% | 18.0–20.5 | +157% ~ +193% | Favorable lawsuit resolution + G9 domestic outperformance + FDA registration advancing: 2027E net profit RMB 200–215 million × 24–26x + net cash RMB 1.75 billion |
Own earnings forecast (reconciliation anchor): FY2026E revenue RMB 960 million–1.02 billion (H2 sequential multiple of 1.32–1.45x, below 2025's 1.69x to reflect the ban and base effects); net profit attributable RMB 90–110 million (assuming FX losses do not repeat materially; will be revised down if RMB keeps appreciating); FY2027E revenue RMB 1.24–1.36 billion, net profit RMB 150–180 million. Benchmarks: CITIC Construction Investment 2026–28E revenue RMB 946 million / 1.256 billion / 1.584 billion, net profit RMB 87 million / 179 million / 242 million; Huachuang target price HK$12 (3x 2026 PS + ~RMB 1.6 billion cash); management gives no quantitative guidance (positive profit alert only). Conclusion: undervalued, target price range HK$11.4–13.5 (= base-case fair value), margin of safety ~63%; quality and price should be judged separately — quality neutral-to-positive (recent profitability inflection, noisy earnings, unresolved patents), price deeply mismatched (EV/S below 1x, growth option ~7%). Expected value ~HK$12.1 (+74%), downside to the bear-case midpoint only ~−18%; odds are significantly skewed to the upside, but the pace of value realization is constrained by item C5 and requires event-by-event verification.
Industry size: CGM (continuous glucose monitoring) is the lowest-penetration, fastest-growing sub-segment among diabetes management devices. The global market was ~US$13.4 billion in 2025 (Grand View Research; the company's annual report cites "over US$12 billion, annual growth 15%+"), expected to reach ~US$41.4 billion by 2033, CAGR ~15%; global 5-year CAGR ~20% (cited in Sinocare's 2025 interim report). The China market was ~RMB 8.0 billion in 2025, potentially reaching ~RMB 17.9 billion by 2030 (Southwest Securities, implied CAGR ~17.5%); retail e-commerce narrow-definition MAT2025 CGM retail sales were RMB 1.54 billion (+45.8%, Mirror data). Demand base: per IDF, ~148 million diabetes patients in China and ~589 million globally (2024, prevalence 11.1%). Penetration is the industry's primary variable: CGM penetration among Type 1 patients in China is ~6.9%, Type 2 ~1.1%, gestational ~0.3% (2020 CIC figures, relayed via brokers), versus US Type 1 at 25.8% and Europe at 18.2% (2020) — a 3–4x gap; the company's annual report states China penetration is "growing at over 20% per year." Two exogenous forces on the payment side: first, from 2025, CGMs were included in the national consumer goods subsidy program (up to 30% subsidy, policy extended into 2026, first tranche of RMB 62.5 billion), which industry estimates will lift volumes by at least 1.5x; second, in-hospital smart glucose management (inpatient hyperglycemia incidence ~38%) opens multi-department use cases. The China insulin pump market was ~US$180 million in 2022, with 80%+ share still held by imported brands such as Medtronic/SOOIL (CIC); replacement of tubed pumps by patch pumps is a structural opportunity (patch pumps already account for 20%+ of the US pump market).
Value chain and profit distribution: Upstream comprises materials and precision processing — glucose oxidase/mediators, flexible probes, semipermeable membranes — with low per-unit cost share and full domestic substitution; the thickest-margin midstream "sensor + transmitter + algorithm" full-stack layer (Dexcom non-GAAP gross margin 61–63%; Medtrum 54.1% → 57.7%) is made in-house by manufacturers and is where patents and know-how are densest; downstream has three channels — in-hospital (endocrinology + whole-hospital glucose management), out-of-hospital retail/e-commerce (Abbott built FreeStyle Libre to RMB 700 million in annual revenue via e-commerce in 2017–2020; Xiaohongshu/Douyin are currently the top customer-acquisition channels), and overseas distribution + reimbursement access. Medtrum sits in the midstream full-stack layer and extends downward into whole-hospital glucose management software (the "Jiantang" system used by 34,000+ healthcare professionals), giving it strong bargaining power upstream; downstream, its consumer brand strength is weaker than Abbott/Sinocare, and overseas it depends on distributor networks — this is the root cause of its still single-digit domestic share and distributor-structure-suppressed overseas margins.
Supply-demand and competitive landscape: A global duopoly — Abbott Diabetes Care FY2025 revenue ~US$7.79 billion (+14.5%), Dexcom US$4.66 billion (+16%); the two companies' combined CGM revenue represents a global CR2 of ~89% (calculated as manufacturers' CGM revenue / global market size, with Libre estimated at ~US$7.3 billion; ±2pp margin of error); Medtronic Diabetes, at US$2.8 billion, ranks third and has announced a spin-off. China's landscape is shifting dramatically: before 2021, Abbott + Medtronic held 90%+; by 2025, domestic brands had captured roughly half of the retail/online market, but in the hospital channel Abbott still holds nearly 80% (April 2024 broker figures) — both figures are presented side by side, and Medtrum's true share depends on channel mix. Domestic first tier: SiBionics (China's #1 by volume 2022–2023, 1 million+ users, MARD 8.83%); Sinocare iCan (2024 sales RMB 200–300 million, first to launch a 15-day product in China, MARD 8.71%); Medtrum (CGM revenue RMB 180 million in 2024 → RMB 452 million in 2025, the fastest growth among leaders — global consolidated basis); Yuwell (Anytime series doubling); a rough calculation on China's RMB 8 billion market puts Medtrum's domestic share at ~3% (estimated, pending verification). Price wars have pushed prices below RMB 100 (per-unit retail 96–123 yuan, promotions as low as 73 yuan, vs 400–600 yuan in 2021); Sinocare's 2025 attributable net profit of −71.6% illustrates the industry-wide cost of trading price for volume — out-of-hospital consolidation is underway, while in-hospital and overseas reimbursement markets remain blue oceans thanks to triple barriers of registration/patent/access. Entry barriers: calibration-free MARD <9% enzyme-membrane chemistry + algorithm iteration (Dexcom G7 15-day MARD ~8.0%), NMPA Class III clinical timelines, FDA iCGM/CE-MDR high standards, Abbott's patent wall (serial UPC litigation), and switching costs from 14–15-day consumable repurchases + closed-loop data ecosystems. Substitutes: BGM has a large installed base but an irreversible information-dimension gap; non-invasive glucose monitoring has no mature commercialized product; GLP-1 and CGM are complementary (expanding the population of Type 2 patients requiring fine-grained monitoring).
Cyclicality and regulation: The industry is in the early growth stage with no typical inventory cycle; momentum is driven by penetration and payment policy. Leading indicators — e-commerce promotion box volumes (Sinocare: 300,000+ boxes in 2024 618 → 400,000+ on Double 11), expansion of subsidized categories and cities, number of hospitals onboarded (Medtrum 3,200+ → 3,600+), overseas registrations/reimbursement approvals, sensor lifespan and MARD iterations (14 → 15 days), whether per-unit prices stabilize at the RMB 100 line, and UPC litigation progress. Regulatory direction: domestically — as of October 2026, CGM has not been included in national or inter-provincial centralized procurement (what has landed are adjacent categories: local procurement of glucose test strips, and the Anhui-led IVD alliance excludes CGM; Anhui's 2025-09 medical service price standardization merely adjusted the in-hospital CGM monitoring billing unit, with payment policy unchanged); the national subsidy is currently the largest payment-side tailwind; NMPA's innovative device expedited review channel accelerates registration (Medtrum's PanCares entered the channel). Overseas — the FDA iCGM framework + OTC availability (from 2024) lowers population thresholds but raises registration standards; CE-MDR is tightening; Abbott is using UPC patent litigation to counter Chinese brands' overseas expansion (triple bans against Sinocare/Medtrum/SiBionics), and European market access competition has escalated from a "registration contest" to a "judicial contest."
Company's industry positioning: First-tier challenger. Share trend is upward (CGM revenue 3.4x over two years); differentiated moat — the only company globally holding both an approved patch insulin pump and a calibration-free real-time CGM (per CIC); the pump–CGM–PanCares closed-loop portfolio is unique in China, and its access assets of 22 Chinese + 101 overseas registration certificates are the deepest among domestic peers. Weaknesses: out-of-hospital consumer brand and channels weaker than Sinocare/Abbott; no FDA iCGM clearance, excluding it from the US market; R&D expense of RMB 76 million (FY2025, −0.3%) is less than a quarter of Sinocare's, so catching up in sensor generations (15-day, MARD ~8.0% tier) depends on investment intensity; the European patent war is its biggest vulnerability. Market-position caveat: the company claims a "leading position in domestic insulin pump systems" (company's own wording), while the industry-wide Chinese pump market is still 80%+ imported (CIC) — the coexistence of both indicates large domestic-substitution room but a still small absolute share for the company.
① Registration pipeline and product iteration: The value cadence of medical devices is determined by registration certificates and generational switching. Medtrum's on-market mainstays are AiDEX X (fully disposable integrated) + LinX (overseas); iteration pipeline: LinX S1 split design (CE obtained 2026-04, reusable transmitter dilutes cost), AiDEX G9 split design (NMPA obtained 2026-09, 15-day wear, MARD 8.66%, modular), AiDEX FLEX (submitted to NMPA/CE), second-generation patch pump (NMPA adult approval 2026-07, waterproofing/reservoir upgrades), and PanCares hybrid closed-loop artificial pancreas (innovative device channel, registration submitted, timing pushed back). The industry's generational arms race: wear time 7 → 14 → 15 days, sampling 5 → 3 minutes, shortened warm-up — each generational iteration directly reshuffles the value-for-money ranking; Medtrum's G9 15-day + split-design combination is first-tier domestically, but MARD 8.66% still trails Dexcom's 8.0%. ② Channel structure: Domestically, a three-pronged push of "3,600+ hospitals (bundled with whole-hospital glucose management software) + e-commerce (618 shipments +157%) + chain pharmacies/O2O"; the rapidly rising out-of-hospital share determines sensitivity to margins and centralized-procurement exposure; overseas is distribution-led (120+ countries, 101 registration certificates, LinX covered by reimbursement in multiple countries), with South Korea (approved 2026-07) and Brazil (approved 2025-12) as 2027 incremental drivers. ③ Payment policy: The national subsidy (up to 30%) is currently the biggest volume lever, with its continuation into 2027 undecided (policy window at end-2026); centralized procurement remains in limbo (see C5); European reimbursement access is the source of overseas margins and the contested prize of the patent war. ④ Cash runway: Net cash of RMB 1.718 billion + positive operating cash flow means no financing/dilution risk — a rare "self-funding" state among 18A companies; unused IPO proceeds of RMB 495 million are committed for deployment by end-2027 (mainly capacity and registrations).
Judgment: Cautiously bullish, confidence level 0.55, time horizon 12–18 months. Rationale summary: the current price of HKD 6.99 represents a 36%–48% discount to the base-case fair value of HKD 11.4–13.5 (implying upside of +63% to +93%), with downside to the bear-case midpoint of approximately −18%; the odds are significantly asymmetric with two layers of reference floors (net cash per share of HKD 4.77 + zero-growth EPV of approximately HKD 6.5). Confidence is deliberately capped at 0.55 — the convergence of the mispricing depends on external events (UPC ruling, annual report delivery, G9 volume ramp, liquidity improvement); delays in any one of these would extend the time cost, and under extremely low liquidity, price discovery itself is distorted. Strategic implication: this is an "event-verification, staged-participation" opportunity, not a trending momentum play; the FY2026 annual report (March 2027) and the progress of the UPC main lawsuit are two hard milestones, while G9 shipments during Double 11 are the nearest falsifiable observation window. Risk warnings (ordered by severity): ① Loss of the UPC main lawsuit or injunction expansion to S1/G9 (European revenue exposure of approximately RMB 120–190 million per year); ② CGM inclusion in centralized procurement (in-hospital ASP −30% to −50% scenario); ③ Domestic price war squeezing gross margin (a gross margin falling below 54% is the warning line); ④ Recurring FX losses (no hedging policy); ⑤ Liquidity risk: average daily turnover of approximately HKD 430,000–2.58 million, far below the 0.1% market cap threshold (approximately HKD 2.9 million/day), making both position building and exit difficult; lack of counterparties in a downturn means value realization may lag fundamentals significantly; ⑥ Controlling shareholder stake reduction and governance concentration. Catalyst calendar:
Monitoring checklist (invalidation conditions): FY2026 net profit attributable to parent < RMB 60 million (falsification of the earnings inflection point); gross margin falling below 54%; loss of the UPC main lawsuit or Abbott obtaining another preliminary injunction against G9/S1; CGM inclusion in provincial alliance/national centralized procurement; 2026 full-year overseas revenue growth < 15%; share price falling below HKD 5.0 (bear-case lower bound, triggering a re-examination of the investment thesis). Monitoring checklist (upside catalysts): G9 Double 11 shipments and pricing; FY2026 annual report net profit ≥ RMB 90 million; PanCares approval; signals of improved liquidity/southbound eligibility; initiation of dividends or scaled-up buybacks; share price reaching HKD 11.4 (lower bound of the base-case range, triggering a re-examination of remaining upside).
This report is based on company announcements, interim reports, annual reports, and public news; prices and market cap are anchored to the 2026-10-09 closing freeze (HKD 6.99), with an RMB/HKD exchange rate of 0.86855. All figures labeled "estimate" are this report's own estimates, not company disclosures.